Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Observational Study
. 2022 Oct;7(10):e008797.
doi: 10.1136/bmjgh-2022-008797.

Twelve-month observational study of children with cancer in 41 countries during the COVID-19 pandemic

Collaborators
Observational Study

Twelve-month observational study of children with cancer in 41 countries during the COVID-19 pandemic

Global Health Research Group on Children’s Non-Communicable Diseases Collaborative. BMJ Glob Health. 2022 Oct.

Abstract

Introduction: Childhood cancer is a leading cause of death. It is unclear whether the COVID-19 pandemic has impacted childhood cancer mortality. In this study, we aimed to establish all-cause mortality rates for childhood cancers during the COVID-19 pandemic and determine the factors associated with mortality.

Methods: Prospective cohort study in 109 institutions in 41 countries.

Inclusion criteria: children <18 years who were newly diagnosed with or undergoing active treatment for acute lymphoblastic leukaemia, non-Hodgkin's lymphoma, Hodgkin lymphoma, retinoblastoma, Wilms tumour, glioma, osteosarcoma, Ewing sarcoma, rhabdomyosarcoma, medulloblastoma and neuroblastoma. Of 2327 cases, 2118 patients were included in the study. The primary outcome measure was all-cause mortality at 30 days, 90 days and 12 months.

Results: All-cause mortality was 3.4% (n=71/2084) at 30-day follow-up, 5.7% (n=113/1969) at 90-day follow-up and 13.0% (n=206/1581) at 12-month follow-up. The median time from diagnosis to multidisciplinary team (MDT) plan was longest in low-income countries (7 days, IQR 3-11). Multivariable analysis revealed several factors associated with 12-month mortality, including low-income (OR 6.99 (95% CI 2.49 to 19.68); p<0.001), lower middle income (OR 3.32 (95% CI 1.96 to 5.61); p<0.001) and upper middle income (OR 3.49 (95% CI 2.02 to 6.03); p<0.001) country status and chemotherapy (OR 0.55 (95% CI 0.36 to 0.86); p=0.008) and immunotherapy (OR 0.27 (95% CI 0.08 to 0.91); p=0.035) within 30 days from MDT plan. Multivariable analysis revealed laboratory-confirmed SARS-CoV-2 infection (OR 5.33 (95% CI 1.19 to 23.84); p=0.029) was associated with 30-day mortality.

Conclusions: Children with cancer are more likely to die within 30 days if infected with SARS-CoV-2. However, timely treatment reduced odds of death. This report provides crucial information to balance the benefits of providing anticancer therapy against the risks of SARS-CoV-2 infection in children with cancer.

Keywords: COVID-19; Cancer; Health systems; Paediatrics.

PubMed Disclaimer

Conflict of interest statement

Competing interests: None declared.

Figures

Figure 1
Figure 1
STROBE flowchart of participants in this study. STROBE, STrengthening the Reporting of OBservational studies in Epidemiology.

References

    1. Birch JM, Marsden HB, Jones PH, et al. Improvements in survival from childhood cancer: results of a population based survey over 30 years. Br Med J 1988;296:1372. 10.1136/bmj.296.6633.1372 - DOI - PMC - PubMed
    1. Saletta F, Seng MS, Lau LMS. Advances in paediatric cancer treatment. Transl Pediatr 2014;3:156–82. 10.3978/j.issn.2224-4336.2014.02.01 - DOI - PMC - PubMed
    1. Pritchard-Jones K, Pieters R, Reaman GH, et al. Sustaining innovation and improvement in the treatment of childhood cancer: lessons from high-income countries. Lancet Oncol 2013;14:e95–103. 10.1016/S1470-2045(13)70010-X - DOI - PubMed
    1. SEER Statistics . Cancer statistics review, 1975-2015. Available: https://seer.cancer.gov/archive/csr/1975_2015/ [Accessed 02 Oct 2020].
    1. Bhakta N, Force LM, Allemani C, et al. Childhood cancer burden: a review of global estimates. Lancet Oncol 2019;20:e42–53. 10.1016/S1470-2045(18)30761-7 - DOI - PubMed

Publication types